mtDNA 8-OHdG | Obstructive CAD N (%) | Non-CAD N (%) | OR (95%CI) | ||
---|---|---|---|---|---|
Model 1a | Model 2b | Model 3c | |||
All participants | |||||
Each 1-SD increase | 1054 | 866 | 1.41 (1.28–1.56) | 1.38 (1.25–1.53) | 1.38 (1.24–1.52) |
Quartiles | |||||
Q1 (< 2.84) | 232 (22.0) | 261 (30.1) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
Q2 (2.84–3.20) | 224 (21.3) | 251 (29.0) | 1.00 (0.78–1.29) | 0.94 (0.72–1.22) | 0.93 (0.71–1.22) |
Q3 (3.20–3.53) | 267 (25.3) | 213 (24.6) | 1.41 (1.10–1.82) | 1.33 (1.02–1.73) | 1.32 (1.01–1.72) |
Q4 (> 3.53) | 331 (31.4) | 141 (16.3) | 2.64 (2.03–3.44) | 2.42 (1.84–3.19) | 2.41 (1.82–3.19) |
P for trend | < 0.001 | < 0.001 | < 0.001 | ||
After PS matching | |||||
Each 1-SD increase | 673 | 673 | 1.39 (1.24–1.56) | 1.39 (1.24–1.55) | 1.39 (1.24–1.55) |
Quartiles | |||||
Q1 (< 2.84) | 149 (22.1) | 187 (27.8) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
Q2 (2.84–3.17) | 148 (22.0) | 190 (28.2) | 0.98 (0.72–1.33) | 0.97 (0.71–1.31) | 0.94 (0.69–1.28) |
Q3 (3.17–3.52) | 163 (24.2) | 176 (26.2) | 1.16 (0.86–1.57) | 1.16 (0.86–1.57) | 1.17 (0.86–1.58) |
Q4 (> 3.52) | 213 (31.7) | 120 (17.8) | 2.22 (1.63–3.04) | 2.19 (1.60–3.00) | 2.18 (1.60–2.99) |
P for trend | < 0.001 | < 0.001 | < 0.001 |